Clinical Trials List
2018-09-01 - 2026-10-02
Phase III
Recruiting5
ICD-10C88.8
Other malignant immunoproliferative diseases
ICD-10C94.40
Acute panmyelosis with myelofibrosis not having achieved remission
ICD-10C94.41
Acute panmyelosis with myelofibrosis, in remission
ICD-10C94.42
Acute panmyelosis with myelofibrosis, in relapse
ICD-10C94.6
Myelodysplastic disease, not classified
ICD-10D46.9
Myelodysplastic syndrome, unspecified
ICD-10D46.A
Refractory cytopenia with multilineage dysplasia
ICD-10D46.B
Refractory cytopenia with multilineage dysplasia and ring sideroblasts
ICD-10D46.C
Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality
ICD-10D46.Z
Other myelodysplastic syndromes
ICD-10D47.1
Chronic myeloproliferative disease
ICD-10D47.3
Essential (hemorrhagic) thrombocythemia
ICD-10D47.9
Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified
ICD-10D47.Z1
Post-transplant lymphoproliferative disorder (PTLD)
ICD-10D47.Z9
Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue
ICD-9238.7
Neoplasm of uncertain behavior of other lymphatic and hematopoietic tissues
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Chi-Ching Chen Division of Hematology & Oncology
- Ming-Hung Tsai Division of Hematology & Oncology
- Ming-Yu Lien Division of Hematology & Oncology
- Che-Hung Lin Division of Hematology & Oncology
- Ching Yun Hsieh Division of Hematology & Oncology
- Tzu-Ting Chen Division of Hematology & Oncology
- Ching-Chan Lin Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- HSIN-CHEN LIN Division of Hematology & Oncology
- ZHENG-WEI ZHOU Division of Hematology & Oncology
- 滕傑林 Division of Hematology & Oncology
- YU-HSUAN SHIH Division of Hematology & Oncology
- Chieh-Lin Teng Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 田豐銘 Division of Hematology & Oncology
- MING YAO Division of Hematology & Oncology
- CHENG-HONG TSAI Division of Hematology & Oncology
- - - Division of Hematology & Oncology
- 徐思淳 Division of Others
- 李思慧 Division of Hematology & Oncology
- Shang-Ju Wu Division of Hematology & Oncology
- - - Division of Hematology & Oncology
- Chieh-Lung Cheng Division of Hematology & Oncology
- Wen-Chien Chou Division of Others -
- Jih-Luh Tang Division of Hematology & Oncology
- Huai-Hsuan Huang Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
15 participants
-
Global
350 participants
